Identifying Vulnerabilities and Novel Drug Candidates in Platinum-Resistant Ovarian Cancer.
View/ Open
Victor_Chiara_Thesis_May2024.pdf (1.172Mb)
Access Status
Full text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.Author
Victor, Chiara Alden
Metadata
Show full item recordCitation
Victor, Chiara Alden. 2024. Identifying Vulnerabilities and Novel Drug Candidates in Platinum-Resistant Ovarian Cancer.. Master's thesis, Harvard University Division of Continuing Education.Abstract
Ovarian cancer is the fifth leading cause of female, cancer-related death in theUnited States and the deadliest form of gynecological cancer (Cancer Facts & Figures
2022, 2022). Epithelial ovarian cancer (EOC) accounts for 90% of all diagnosed ovarian
cancers, 70% of which are High Grade Serous Ovarian Cancer (HGSOC), with a five-
year survival rate less than 25% (Cai et al., 2014; Ediriweera et al., 2019; Iyengar et al.,
2018; Lisio et al., 2019; Siwak et al., 2010). Platinum-taxane combination therapy has
been the standard of care since its introduction in the 1990s yet, over 70% of HGSOC
patients relapse due to platinum resistance (PR) (Kim et al., 2012; Kristedja et al., 2010;
Moghbeli, 2021). There is a critical need for alternative therapeutic options for PR
HGSOC. Here, we aimed to generate models of PR from HGSOC cell lines intrinsically
sensitive to cisplatin and screen them against a panel of 225 small molecule inhibitors.
The panel consists of FDA-approved drugs currently being used clinically, drugs in
Phase II or III clinical trials, as well as novel-preclinical small molecule kinase inhibitors
and tool compounds to identify single agents and/or pathways of interest in combating
PR. Aligning with previous research, selective EGFR and PI3K inhibitors elicited
significant responses in the PR model compared to the parental cell line. Lastly, the MEK
inhibitor, cobimetinib, displayed advantageous responses in the PR model and highlight
the MEK pathway to be further investigated in the context of PR HGSOC.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37378525
Collections
- DCE Theses and Dissertations [1331]
Contact administrator regarding this item (to report mistakes or request changes)